During the index procedure a resolute onyx des was implanted in the lad.During a revascularization procedure two resolute onyx des were implanted in the rca.During a second revascularization procedure one resolute onyx des was implanted in the rca and one resolute onyx des was implanted in the rpl.During a third revascularization procedure two resolute onyx des were implanted in the rca.During a fourth revascularization procedure one resolute integrity bms as implanted in the rca.During a fifth revascularization procedure to treat severely calcified rca and intent restenosis of the mid rca plaque prolapse was noted and the patient was treated with two medtronic stents in the rca.The plaque prolapse was not present prior to the stent in the mid rca, prolapse occurred after the post dilation of mid rca.Plaque prolapse caused occlusion in the ostial rca therefore ostial rca was stented.The patient was discharged home.Investigator assessed the event as not related to index device or anti-platelet medication.The sponsor assessed the event as not related to the anti-platelet medication and unlikely related to the index device.The plaque prolapse was not present prior to the stent in the mid rca, prolapse occurred after the post dilation of mid rca.Plaque prolapse caused occlusion in the ostial rca therefore ostial rca was stented.
|
Correction: during a revascularization procedure one integrity bms was implanted in the rca.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|